MBL2 gene variants coding for mannose-binding lectin deficiency are associated with increased risk of nephritis in Danish patients with systemic lupus erythematosus
Restricted accessResearch articleFirst published online October, 2014
MBL2 gene variants coding for mannose-binding lectin deficiency are associated with increased risk of nephritis in Danish patients with systemic lupus erythematosus
Autoimmunity may in part result from deficiencies in the processing of apoptotic debris. As mannose-binding lectin (MBL) is involved in such processes, we hypothesized that the variants in the MBL2 gene resulting in MBL deficiency confer an increased risk of nephritis in systemic lupus erythematosus (SLE).
Methods
A total of 171 SLE patients attending a Danish tertiary rheumatology referral center were included. Common variant alleles in exon 1 of the MBL2 gene (R52C, rs5030737; G54D, rs1800450; G57E, rs1800451) were genotyped. The normal allele and variant alleles are termed A and O, respectively. The follow-up period was defined as the time from fulfillment of the ACR 1987 classification criteria for SLE until the occurrence of an event (nephritis, end-stage renal disease (ESRD), or death) or end of follow-up. Cox regression analyses were controlled for gender, age and race.
Results
During a median follow-up of 5.7 years, nephritis developed in 94 patients, and ESRD developed in 16 of these patients. Twenty-seven patients died. The distribution of the MBL2 genotypes A/A, A/O and O/O was 58%, 35% and 7.0%, respectively. Compared to the rest, O/O patients had 2.6 times (95% CI: 1.2–5.5) higher risk of developing nephritis, and their risk of death after 10 years was 6.0 times increased (95% CI: 1.0–36). MBL serum levels below 100 ng/ml were associated with a 2.0 (95% CI: 1.2–3.4; p = 0.007) increased risk of developing nephritis. ESRD and histological class of nephritis were not associated with MBL deficiency.
Conclusions
Genetically determined MBL deficiency was associated with development of nephritis in SLE patients, but not with histological class of nephritis or ESRD.
RahmanAIsenbergDA. Mechanisms of disease systemic lupus erythematosus. N Engl J Med2008; 358: 929–939.
2.
ChoiJKimTKCraftJ. The pathogenesis of systemic lupus erythematosus—an update. Curr Opin Immunol2012; 24: 651–657.
3.
GilesBMBoackleSA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res2013; 55: 10–12.
4.
JacobsenSPetersenJUllmanS. A multicentre study of 513 Danish patients with systemic lupus erythematosus. Disease manifestations and analyses of clinical subsets. Clin Rheumatol1998; 17: 468–477.
5.
TangSLuiSLLaiKN. Pathogenesis of lupus nephritis: An update. Nephrology2005; 10: 174–179.
6.
YungSChanTM. Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: Getting to know the unknown. Clin Dev Immunol2012; 2012: 139365–139365.
7.
JacobsenSStarklintHPetersenJ. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand J Rheumatol1999; 28: 288–299.
8.
FaurschouMStarklintHHalbergPJacobsenS. Prognostic factors in lupus nephritis: Diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol2006; 33: 1563–1569.
9.
SeretGLe MeurYRenaudineauYYouinouP. Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis. Clin Dev Immunol2012; 2012: 579670–579670.
10.
JørgensenMHRekvigOPJacobsenRSJacobsenSFentonKA. Circulating levels of chromatin fragments are inversely correlated with anti-dsDNA antibody levels in human and murine systemic lupus erythematosus. Immunol Lett2011; 138: 179–186.
11.
FismenSHedbergAFentonKA. Circulating chromatin-anti-chromatin antibody complexes bind with high affinity to dermo-epidermal structures in murine and human lupus nephritis. Lupus2009; 18: 597–607.
12.
ThiyagarajanDFismenSSeredkinaN. Silencing of renal DNaseI in murine lupus nephritis imposes exposure of large chromatin fragments and activation of Toll like receptors and the Clec4e. PLoS One2012; 7: e34080–e34080.
13.
AndradeFCasciola-RosenLRosenA. Apoptosis in systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am2000; 26: 215–227.
14.
NautaAJRaaschou-JensenNRoosA. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol2003; 33: 2853–2863.
15.
MandersonAPBottoMWalportMJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol2004; 22: 431–456.
GarredP. Mannose-binding lectin genetics: from A to Z. Biochem Soc Trans2008; 36: 1461–1466.
18.
GarredPLarsenFSeyfarthJFujitaRMadsenHO. Mannose-binding lectin and its genetic variants. Genes Immun2006; 7: 85–94.
19.
GarredPVossAMadsenHOJunkerP. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun2001; 2: 442–450.
20.
GarredPMadsenHOHalbergP. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum1999; 42: 2145–2152.
21.
ØhlenschlægerTGarredPMadsenHOJacobsenS. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med2004; 351: 260–267.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
24.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
25.
TroelsenLNGarredPChristiansenBTorp-PedersenCJacobsenS. Genetically determined serum levels of mannose-binding lectin correlate negatively with common carotid intima-media thickness in systemic lupus erythematosus. J Rheumatol2010; 37: 1815–1821.
26.
HommelKRasmussenSMadsenMKamperAL. The Danish Registry on regular dialysis and transplantation: Completeness and validity of incident patient registration. Nephrol Dial Transplant2010; 25: 947–951.
27.
AustinHA3rdMuenzLRJoyceKM. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med1983; 75: 382–391.
28.
MillerSADykesDDPoleskyHF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res1988; 16: 1215–1215.
29.
GarredPMadsenHOSvejgaardAGenetics of human mannan-binding protein. In: EzekowitzRABSastryKReidKBM (eds). Collectins and innate immunity, Austin, TX: R.G. Landes, 1996, pp. 139–164.
30.
GarredPStromJQuistLTaaningEMadsenHO. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis2003; 188: 1394–1403.
31.
SumiyaMSuperMTabonaP. Molecular basis of opsonic defect in immunodeficient children. Lancet1991; 337: 1569–1570.
32.
LipscombeRJSumiyaMHillAV. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet1992; 1: 709–715. Erratum, Hum Mol Genet 1993; 2: 342.).
33.
GarredPMadsenHOKurtzhalsJAL. Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogenet1992; 19: 403–412.
34.
BouwmanLHRoepBORoosA. Mannose-binding lectin: Clinical implications for infection, transplantation, and autoimmunity. Hum Immunol2006; 67: 247–256.
35.
VillarrealJCrosdaleDOllierW. Mannose binding lectin and FcgammaRIIa (CD32) polymorphism in Spanish systemic erythematosus patents. Rheumatology2001; 40: 1009–1012.
36.
Sandrin-GarciaPBrandãoLACoelhoAV. Mannose binding lectin gene (MBL2) functional polymorphisms are associated with systemic lupus erythematosus in southern Brazilians. Hum Immunol2011; 72: 516–552.
37.
TsaiYCYehKWYaoTCHuangYLKuoMLHuangJL. Mannose-binding lectin expression genotype in pediatric-onset systemic lupus erythematosus: Associations with susceptibility to renal disease and protection against infections. J Rheumatol2011; 38: 1429–1435.
38.
JacobsenSPetersenJUllmanS. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus. Scand J Rheumatol1999; 28: 75–80.
39.
FaurschouMMellemkjaerLStarklintH. High risk of ischemic heart disease in patients with lupus nephritis. J Rheumatol2011; 38: 2400–2405.
40.
PandaAKParidaJRTripathyRPattanaikSSRavindranBDasBK. Mannose binding lectin: A biomarker of systemic lupus erythematosus disease activity. Arthritis Res Ther2012; 14: R218–R218.
41.
TroelsenLNJacobsenSAbrahamsJL. IgG glycosylation changes and MBL2 polymorphisms: Associations with markers of systemic inflammation and joint destruction in rheumatoid arthritis. J Rheumatol2012; 39: 463–469.
42.
JacobsenSGarredPMadsenHO. Mannose-binding lectin gene polymorphisms are associated with disease activity and physical disability in untreated, anti-cyclic citrullinated peptide-positive patients with early rheumatoid arthritis. J Rheumatol2009; 36: 731–735.
